[Hemoglobin variability in patients with chronic renal insuffiency]

Nephrol Ther. 2008 Dec;4(7):549-52. doi: 10.1016/j.nephro.2008.04.010. Epub 2008 Nov 11.
[Article in French]

Abstract

Several recent articles have examined the time-dependent effects of epoetin therapy and the variability of hemoglobin (HGb) levels and what epoetin does in hemodialysis patients. A recent preliminary report also found that HGG cycling was common among hemodialysis patients, with only 10% of patients remaining within their initial HGb range (less than 11 g/dl, 11 to 12.5 g/dl, greater than 12.5 g/dl) during a six-month period. Factors associated with HGb cycling were changes in epoetin dose, intravenous-iron administration or a change in dose and hospitalization. What is not known is whether there are adverse clinical outcomes associated with HGb variability, although preliminary data indicate, perhaps predictably, that a decreasing HGb level is associated with a higher mortality risk. This is certainly an area that merits further study.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Epoetin Alfa
  • Erythropoietin / therapeutic use*
  • Hematinics / therapeutic use
  • Hemoglobins / drug effects
  • Hemoglobins / metabolism*
  • Humans
  • Kidney Failure, Chronic / blood*
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Recombinant Proteins
  • Renal Dialysis

Substances

  • Hematinics
  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Epoetin Alfa